S-1 Monotherapy as Second- or Third-Line Chemotherapy for Unresectable and Recurrent Esophageal Squamous Cell Carcinoma

Publisher： Karger

E-ISSN： 1423-0232|84|5|305-310

ISSN： 0030-2414

Source： Oncology, Vol.84, Iss.5, 2013-04, pp. : 305-310

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Recurrent Syncope due to Esophageal Squamous Cell Carcinoma

By  

Case Reports in Oncology, Vol. 4, Iss. 3, 2011-09 ,pp. : 433-438

Karger

Access to resources Recommend Favorite

Selection of a Patient Subgroup with Advanced Esophageal Squamous Carcinoma Who Could Benefit from Second-Line Chemotherapy

By  

Oncology, Vol. 79, Iss. 5-6, 2011-03 ,pp. : 363-369

Karger

Access to resources Recommend Favorite

First-Line Chemotherapy for Metastatic Esophageal Squamous Cell Carcinoma: Clinico-Biological Predictors of Disease Control

By  

Oncology, Vol. 90, Iss. 2, 2016-0 ,pp. : 88-96

Karger

Access to resources Recommend Favorite

A Phase II Study of Third-Line Combination Chemotherapy with Bevacizumab Plus S-1 for Metastatic Colorectal Cancer with Mutated KRAS (SAVIOR Study)

By  

Oncology, Vol. 91, Iss. 1, 2016-05 ,pp. : 24-30

Karger

Access to resources Recommend Favorite

Case of pure ovarian squamous cell carcinoma resistant to combination chemotherapy with paclitaxel and carboplatin but responsive to monotherapy with weekly irinotecan

By  

JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH (ELECTRONIC), Vol. 41, Iss. 5, 2015-05 ,pp. : 809-812

John Wiley & Sons Inc

Access to resources Recommend Favorite